Cofoe Medical Technology Co., Ltd. (COFOE MEDICAL) reported that the registration procedures for cancelling 397,000 A-shares repurchased under its 2022 buy-back programme were completed on 10 November 2026, according to the Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 11 November 2026.
Prior to the cancellation, total issued shares stood at 208.90 million, comprising 203.77 million issued shares and 5.12 million treasury shares. Following the cancellation, total issued shares declined by 0.19 % to 208.50 million, while treasury shares fell to 4.73 million. The number of issued shares outstanding (excluding treasury stock) remained unchanged at 203.77 million.
Repurchases Pending Cancellation Eight tranches of shares bought back between 22 July and 2 September 2026—amounting to 2.60 million shares, or roughly 1.25 % of the current share base—have not yet been cancelled. The weighted-average repurchase price for these shares is estimated at RMB 51.66 per share, implying an aggregate consideration of about RMB 134.22 million.
Regulatory Compliance The company confirmed that all share cancellations and repurchases were authorised by the board and executed in accordance with listing rules, relevant laws and regulatory requirements.
Comments